Cargando…

Serum vascular endothelial growth factor changes and safety after topical anti‐human VEGF antibody bevacizumab in healthy dogs

OBJECTIVE: To evaluate ocular and general safety of topical anti‐human VEGF bevacizumab and the effect on serum vascular endothelial growth factor (VEGF) values in healthy dogs. PROCEDURES: Nine university‐owned beagles received 0.05 mL of 0.25% bevacizumab eyedrops (Avastin(®), Roche) in one eye an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muellerleile, Lisa‐Marie, Tichy, Alexander, Nell, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850477/ https://www.ncbi.nlm.nih.gov/pubmed/30716185 http://dx.doi.org/10.1111/vop.12628

Ejemplares similares

Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series
por: Muellerleile, Lisa‐Marie, et al.
Publicado: (2021)

Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization
por: Lessiak, Ulrike, et al.
Publicado: (2023)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

Quantitative, noninvasive assessment of intra‐ and extraocular perfusion by contrast‐enhanced ultrasonography and its clinical applicability in healthy dogs
por: Blohm, Klaas‐Ole, et al.
Publicado: (2019)

The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer
por: Goulart, André, et al.
Publicado: (2019)

Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis
por: Nagai, Toshihiro, et al.
Publicado: (2014)

Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
por: Rusovici, Raluca, et al.
Publicado: (2011)

Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab
por: Wang, Donghyun, et al.
Publicado: (2014)

Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?
por: Sümbül, Ahmet Taner, et al.
Publicado: (2014)

Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.
por: Obermair, A., et al.
Publicado: (1998)

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells
por: Jun, Jong Hwa, et al.
Publicado: (2016)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)

Immunohistochemical staining of immunoglobulin G in healthy equine, canine, and feline corneas
por: Herb, Verena Maria, et al.
Publicado: (2022)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)

Clinical utility, dose determination, and safety of ocular contrast‐enhanced ultrasonography in horses: A pilot study
por: Blohm, Klaas‐Ole, et al.
Publicado: (2019)

Serum vascular endothelial growth factor in dogs with various proliferative diseases
por: HORIKIRIZONO, Hiro, et al.
Publicado: (2022)

Methodological Concerns Regarding Levels of Vascular Endothelial Growth Factor (VEGF) in Serum of Women with Endometriosis
por: Leone Roberti Maggiore, Umberto, et al.
Publicado: (2015)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.
por: Yamamoto, S., et al.
Publicado: (1997)

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
por: Ding, Yi, et al.
Publicado: (2022)

Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye
por: Jiang, Xiaodan, et al.
Publicado: (2015)

The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion
por: Düzköprü, Yakup, et al.
Publicado: (2017)

Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response
por: Silva, Tábata Almeida, et al.
Publicado: (2022)

Short Communication: Interaction of Nerve Growth Factor (NGF) and Vascular Endothelial Growth Factor (VEGF) in Healthy Individuals
por: Groh, Adrian, et al.
Publicado: (2019)

Expression of vascular endothelial growth factor (VEGF) in equine sarcoid
por: Martano, Manuela, et al.
Publicado: (2018)

VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
por: Barratt, Shaney L., et al.
Publicado: (2018)

Vascular Endothelial Function Is Not Related to Serum Uric Acid in Healthy Adults
por: Jalal, Diana I., et al.
Publicado: (2012)

Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair
por: Nagai, Toshihiro, et al.
Publicado: (2010)

Serum Vascular Endothelial Growth Factor (VEGF-C) as a Diagnostic and Prognostic Marker in Patients with Ovarian Cancer
por: Cheng, Daye, et al.
Publicado: (2013)

Evaluation of vascular endothelial growth factor (VEGF) level in the tears and serum of age-related macular degeneration patients
por: Shahidatul-Adha, Mohamad, et al.
Publicado: (2022)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
por: Krizova, Deli, et al.
Publicado: (2014)

An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia
por: Sadick, Haneen, et al.
Publicado: (2022)

Anti-TNF-α antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor (VEGF) levels in patients with rheumatoid arthritis: a pilot study
por: Strunk, J, et al.
Publicado: (2004)

Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF
por: Man, Xiao-Yong, et al.
Publicado: (2008)

Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis
por: Machado, Daniel Escorsim, et al.
Publicado: (2015)

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
por: Schmidinger, Manuela
Publicado: (2013)

Association of Chemerin and Vascular Endothelial Growth Factor (VEGF) with Diabetic Nephropathy
por: Lin, Shuhua, et al.
Publicado: (2016)

Topical Ripasudil for the Treatment of Primary Corneal Endothelial Degeneration in Dogs
por: Michalak, Sarah R., et al.
Publicado: (2022)

Anti‐bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor‐binding response, impairing tumor outgrowth
por: Sanches, Jéssica de Souza, et al.
Publicado: (2016)

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).
por: Стародуб, Галина, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q23900fqi4oe6hc0oqp21hi1nj